Our work is also in line with Zhang et al., who showed that luseogliflozin, an SGLT2 inhibitor, ameliorates renal fibrosis after prolonged renal I/R injury in nondiabetic mice10. This evidence concerns the gene SLC5A2 and renal fibrosis.